首页|布洛芬与酮替芬联合治疗上呼吸道感染的疗效观察及其对炎症因子的影响

布洛芬与酮替芬联合治疗上呼吸道感染的疗效观察及其对炎症因子的影响

The clinical effect and impact on inflammatory factors by Anti-inflammatory agent treatment in upper respiratory tract infection patients

扫码查看
目的:探讨布洛芬与酮替芬(抗炎合剂)联合治疗上呼吸道感染的疗效与及其对炎症因子的影响。方法:将120例上呼吸道感染患者随机分为两组组和常规治疗组,于治疗后第3天观察疗效,第1和第5天分别用ELISA法和免疫层析法检测白介素-1和降钙素原水平。结果:布洛芬与酮替芬联合治疗组(抗炎合剂组)临床总有效率比较高,复诊率比较低,IL-1明显下降,较常规治疗组明显(P<0.05),降钙素原治疗前后无明显变化,两组也无差别(P>0.05)。结论:布洛芬与酮替芬联合治疗上呼吸道感染临床效果明显,并能抑制IL-1水平。
Objective:To investigate The clinical effect and impact on inflammatory factors by Anti-inflammatory agent treatment in upper respiratory tract infection patients.Methods:120 patients with upper respiratory tract infection were randomly divided into two groups, anti-inflammatory agent group and the conventional treatment group.The clinical effect was observed three days later.On the 1st and 5th day after the treatment began, IL-1 and PCT were respectively detected by ELISA and immunochromatography assay.Results:Clinical effective rate is relatively higher, referral rate is relatively lower, IL-1 significantly decreased, in the Anti-inflammatory agents group than the conventional treatment group (P<0.05).PCT was not significant change before and after treatment, and no Difference between the two groups (P> 0.05) Conclusion:The anti-inflammatory agents can inhibit IL-1 levels,and the clinical effect is obvious in the upper respiratory infection patients.

upper respiratory tract infection(AURI)interleukin-1(IL-1)procalcitonin(PCT)

郑贵浪

展开 >

广东医学院附属医院儿童医学中心

上呼吸道感染 白介素-1 降钙素原

2013

中国保健营养(中旬刊)
全国卫生产业企业管理协会

中国保健营养(中旬刊)

ISSN:1004-7484
年,卷(期):2013.(12)
  • 2